Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.
1. A compound of formula:
or a pharmaceutically acceptable salt thereof.
2. A compound of formula:
or a pharmaceutically acceptable salt thereof.
3. A compound of formula:
4. A compound of formula:
5. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt of claim 1 .
6. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt of claim 2 .
7. A pharmaceutical composition comprising the compound of claim 3 .
8. A pharmaceutical composition comprising the compound of claim 4 .
9. A method of treating a Pneumovirinae virus infection in a human, the method comprising administering to the human a therapeutically effective amount of the compound or the pharmaceutically acceptable salt of claim 1 .
10. The method of claim 9 , wherein the Pneumovirinae virus infection in the human is a human respiratory syncytial virus infection.
11. A method of treating a Pneumovirinae virus infection in a human, the method comprising administering to the human a therapeutically effective amount of the compound or the pharmaceutically acceptable salt of claim 2 .
12. The method of claim 11 , wherein the Pneumovirinae virus infection in the human is a human respiratory syncytial virus infection.
13. A method of treating a Pneumovirinae virus infection in a human, the method comprising administering to the human a therapeutically effective amount of the compound of claim 3 .
14. The method of claim 13 , wherein the Pneumovirinae virus infection in the human is a human respiratory syncytial virus infection.
15. A method of treating a Pneumovirinae virus infection in a human, the method comprising administering to the human a therapeutically effective amount of the compound of claim 4 .
16. The method of claim 15 , wherein the Pneumovirinae virus infection in the human is a human respiratory syncytial virus infection.